A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response

A newly published study has introduced an interesting variation on antibody-drug conjugates (ADCs) for advanced prostate cancer: instead of simply delivering a toxic payload to cancer cells, the treatment is designed to help the immune system recognise what remains. The experimental ADC targets STEAP1, a cell-surface protein highly expressed in prostate cancer and already being […]

Reprogramming Cancer, Decoding DNA: Two Promising New Frontiers in Cancer Research

Two important scientific developments, published last week, offer a glimpse of where prostate cancer research could be heading, even though both remain firmly in the experimental or preclinical arena. The first comes from Adelaide University, where researchers have developed “smart” lipid nanoparticles designed to reprogramme tumour-associated macrophages, immune cells that cancers can exploit to suppress […]

Drugging the Undruggable in Prostate Cancer

Many proteins that drive cancer are considered “undruggable” because they lack the pockets that conventional drugs need to bind and block them. A new approach in prostate cancer attempts to bypass this problem: instead of inhibiting a cancer-driving protein, make the cell destroy it. Researchers have developed a protein degrader (against an undisclosed protein) believed […]

Reading the DNA Fingerprints of Prostate Cancer

Prostate cancer does not develop in the same way in every patient. Different biological processes can damage the DNA of cancer cells, leaving behind characteristic patterns, or “mutational signatures.” A recent study, published on Nature, used whole-genome sequencing to combine these patterns and identify eight integrated mutational footprints (IMFs), providing a broader picture of how […]

Beyond CRISPR? TIGRa: The Tiny Genetic Switch That Could Let the Body Heal Itself

Scientists at Stanford Medicine have built a new tool called TIGRa that can switch on helpful genes directly inside living cells. In a mouse study, it helped protect the eyes from a type of damage seen in glaucoma, and the discovery was published in the journal Cell Stem Cell. It could eventually lead to treatments […]

Forcing Resistant Prostate Cancer Back into Treatment Range: eIF4E Could Help

Prostate cancer often becomes dangerous because the tumor cells can change their identity to escape treatment. At first, most prostate cancers are “luminal”: they depend on the androgen receptor (AR), a protein that acts like a growth switch turned on by male hormones. Drugs that block this receptor, such as enzalutamide, usually work well at […]

Drug Combination Shows Promise Against Treatment-Resistant Prostate Cancer

A University of Michigan study suggests that combining two types of drugs could offer a new approach to treating advanced, treatment-resistant prostate cancer. The research focused on tumors that have changed their identity through a process called transdifferentiation. These tumors can become more aggressive and may no longer respond well to standard treatments that target […]

How Prostate Cancer Hijacks Amino Acids to Beat Hormone Therapy

Prostate cancer cells can outsmart hormone therapy by rewiring how they use nutrients, and a new preclinical study from Weill Cornell Medicine shows exactly how. Published in Nature Metabolism, the work reveals that tumors hijack the metabolism of two common amino acids, isoleucine and valine, to boost cholesterol production inside the tumor. That extra cholesterol […]

SCD1 Inhibition May Strengthen Enzalutamide Against Resistant Prostate Cancer

SCD1 is an enzyme that helps prostate-cancer cells convert saturated fatty acids into monounsaturated fatty acids, which support cell membranes, energy storage and survival signaling. Functional research suggests that some tumors rely on SCD1 activity. Blocking this pathway can disrupt lipid synthesis, androgen-receptor signaling and survival pathways such as AKT. This provides the rationale for […]

B7-H3: A Continuum-Wide, AR-Repressed Anchor for Combinatorial Prostate Cancer Therapy

A landmark 2026 study in Clinical Cancer Research reframes surface-target therapy in advanced prostate cancer by placing B7-H3 (CD276) at the center of a continuum-wide strategy. Integrating the JHU-PANORAMA single-cell atlas (~1M cells, 213 patients) with patient-derived xenografts, metastatic rapid-autopsy tissues, and mechanistic cell-line work, the authors show that B7-H3 is the most uniformly expressed […]